logo
Stimulant Medications Don't Cause Psychosis, New Study Finds

Stimulant Medications Don't Cause Psychosis, New Study Finds

Medscape14-05-2025
Prescription stimulants taken during childhood for attention-deficit/hyperactivity disorder (ADHD) do not cause psychosis, according to a new study published on Monday in Pediatrics, contradicting what some observational studies had suggested.
Instead, the new study found children with more severe attention and hyperactivity issues or other mental health conditions such as anxiety were more likely to be medicated for ADHD. These children were also more likely to experience psychotic episodes, suggesting stimulants such as Adderall were not the cause.
'These results provide reassurance both to families and to prescribers that routine ADHD medication treatment is unlikely to cause psychotic experiences,' said Ian Kelleher, PhD, chair of child and adolescent psychiatry in the Centre for Clinical Brain Sciences at The University of Edinburgh in Edinburgh, Scotland, who led the trial.
Kelleher and his colleagues used data from the Adolescent Brain Cognitive Development Study, a longitudinal study tracking brain development and child health in the United States. The study included more than 8300 children and teens who were between 9 years and 14 years of age from 2016 to 2020.
At the beginning of the study, none of the children were taking a prescription stimulant. In the first year, 460 kids were prescribed a drug for ADHD, which included methylphenidate, dexmethylphenidate, amphetamine, dextroamphetamine, and lisdexamfetamine. They did not have information on the dose of medication. Researchers then compared rates of psychosis among these children with approximately 7900 children who were not on one of these medications.
The researchers analyzed self-reported questionnaires from each child, which they filled out at baseline and again 1 year into the study. The screener for psychosis risk asked 21 questions about whether they had experienced hallucinations or delusions, and if so, how distressed they were by these experiences.
Among the population taking stimulants, the drugs were not associated with psychosis after adjusting for confounding factors that can predispose a person to psychosis, including mental illness, parental income, and race (odds ratio [OR], 1.09; 95% CI, 0.71-1.56).
In the unweighted analysis, children prescribed ADHD medications were about 1.5 times more likely to have had a psychotic episode than those not taking a stimulant (OR, 1.46; 95% CI, 1.15-1.84).
Those who had more severe ADHD symptoms, like hyperactivity or impulsiveness, and those who had other, co-occurring mental health symptoms like anxiety and depression, were most likely to report psychotic episodes. This group, as well as boys generally, were also more likely to have been prescribed stimulants.
'It's important to recognize that any difference in risk may not be due to stimulant treatment,' Kelleher said. 'If you take children with ADHD and you divide them into two groups, kids treated with medication and kids not treated with medication, those two groups are not the same.'
Kelleher said previous research linking stimulants with episodes of psychosis had not done a thorough job of factoring in a person's mental health or severity of ADHD.
One observational study published in 2024 suggested higher doses of prescription amphetamines were associated with more than a fivefold increase in the risk of developing psychosis.
A 2023 meta-analysis also cited studies suggesting taking higher doses of stimulants than typically prescribed for ADHD could cause psychosis. An observational study published in 2024, in the Journal of the American Academy of Child & Adolescent Psychiatry , concluded that while risk for psychosis was low, taking amphetamines and atomoxetine for longer periods of time may increase a person's risk for psychosis. However, the authors of the meta-analysis did note that clinicians may have misidentified a child's symptoms as ADHD instead of signs of psychosis.
In addition to factors like race and age, researchers should consider that hallucinations and delusions are 'quite common' during childhood, said Melissa Batt, MD, MPH, an assistant professor of psychiatry at the University of Colorado Anschutz Medical Campus, Aurora, Colorado, who was not involved with the trial. They should take this knowledge into account when looking into potential causes of psychotic episodes in kids.
'They are usually fleeting and usually go away,' Batt said, adding that only a small number of young people who report having a psychotic episode are eventually diagnosed with a psychotic disorder. 'Upwards of 90% do not go on to have a diagnosis,' she said.
Batt said one limitation of the study was the 9- to 14-year-old age range.
'They are missing a pretty critical range of folks, especially older teens and people in their 20s. Those are the ages that we see who develop psychosis or mania,' she said.
Batt agreed observational studies left out a lot of factors that could connect psychotic episodes to influences other than stimulant medications. Family history, she said, is a huge influence in whether a person develops a psychotic disorder.
Future trials should build on these new findings and take different patient characteristics into account, she said.
'We should be looking at family history, other medications they are taking, they could be using other substances such as cannabis, which they didn't control for,' she said. 'That is a huge variable we should be looking at.'.
This study was funded in part by an International Secondment Award to J.F.B. from the Royal College of Surgeons in Ireland University of Medicine and Health Sciences. The study authors reported receiving financial support from the St John of God Research Foundation and the Health Research Board, among others.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

More elderly Americans are choking to death. Are these devices the answer?
More elderly Americans are choking to death. Are these devices the answer?

Associated Press

time43 minutes ago

  • Associated Press

More elderly Americans are choking to death. Are these devices the answer?

NEW YORK (AP) — It was the scariest choking incident David Palumbo had ever seen. The 88-year-old man had been dining at a Providence, Rhode Island, Italian restaurant in September 2019. Now he was unconscious, with a piece of bread lodged in his windpipe. Precious minutes went by as first responders were unable to help him with CPR or the Heimlich maneuver. In an ambulance on the way to the hospital, the elderly man's skin was blue, and firefighters worried he was going to die. Palumbo — a fire department captain — used a scissors-like device called Magill forceps to pull the bread from the man's throat. 'We get a lot of calls in the city for choking,' many of which are resolved before emergency responders even get there, Palumbo added. 'This was by far the worst one I've been on in my career.' Fortunately, the man survived and made a full recovery, he said. But many elderly people do not. Each year, choking claims the lives of more than 4,100 Americans who are 65 or older. It's the most vulnerable age group, accounting for about three-quarters of U.S. choking deaths, according to federal health statistics. The death rate has been relatively steady, but the number has risen, as the size of the nation's retirement-age population grows. In response, a number of companies are marketing antichoking devices to the elderly. Medical professionals have been debating whether to endorse the products, sold under the names LifeVac, SaveLix, VitalVac and the Dechoker. Dr. Nathan Charlton, a University of Virginia professor of emergency medicine who advises the American Red Cross on first aid, said there is limited evidence for the products and that the Red Cross is still evaluating them. Here's a look at choking and the best ways to prevent choking deaths. Choking is a danger to older adults Choking occurs when food or some other object partially or totally blocks the windpipe, preventing oxygen from reaching the lungs. Telltale signs include someone reaching for their neck and losing the ability to speak normally. Brain damage can occur after four minutes, and death can come just a few minutes later. Older adults are at higher risk for a number of reasons. As people get older, mouth and throat muscles can weaken. Older people also make less saliva. Some chronic diseases and medications can make swallowing even harder. Dentures can be a choking risk. The best ways to stop choking Choking risk can be reduced by cutting food into small pieces, chewing food slowly, drinking plenty of liquids with meals, and not laughing or talking at the same time you are chewing and swallowing. When someone is choking, you can try perhaps the oldest form of first aid: back slaps. There's also the Heimlich maneuver, named after the doctor credited with devising it in the 1970s. It involves standing behind the choking person, wrapping your arms around their abdomen and — with a balled fist — thrusting inward and upward. The idea is that it forces air out of the lungs, and the obstruction with it. The American Red Cross recommends alternating back blows and abdominal thrusts in sets of five. That's for situations in which someone is around to help a choking victim. But what if they are alone? It is possible for someone try to self-administer a Heimlich by thrusting their abdomen against the back of a chair, Charlton said. Makers of some the newer anti-choking devices say that's where their products can make a difference. 'Elderly people probably are not capable of diving on a chair or counter,' said Arthur Lih, the founder and chief executive of LifeVac. Antichoking devices aren't always risk-free They vary in design, but generally the devices look like a face mask attached to a tube or bellows, with a handle at the end. They typically sell for around $30 to $100. A choking person dons the mask, pushes down on the handle and then pulls up. That is supposed to create a suction that would pull out the blockage. Some research suggests at least certain devices can injure the tongue or cause bleeding and swelling in the throat. And the U.S. Food and Drug Administration has reports that some products did not generate enough suction and left people with bruising around the face, lips, and mouth. An injury report led the FDA to do an inspection and issue a warning letter to Dechoker in 2021. Manufacturers note their products are registered with the FDA, but that's not the same as an endorsement. Indeed, the agency last year issued a notice to consumers that said it has not approved antichoking devices sold over the counter, because their safety and effectiveness haven't been established. Lih said the FDA action was in response to the proliferation of antichoking devices entering the market that vary in design and quality. More research is needed, choking expert says Right now, the consensus — even among antichoking device manufacturers — is that back blows and abdominal thrusts should always be tried first. (The forceps that Palumbo used are not recommended for the general public.) Lih said thousands of nursing homes and emergency response agencies have purchased the newer antichoking devices. One example: The police department in Acworth, Georgia, bought about 75 LifeVac devices after an officer last year used her personal device to save an elderly woman. They are now in every patrol car, said Sgt. Eric Mistretta. Manufacturers claim the products have saved thousands of lives across multiple countries, but it's tricky to document how well they actually work, said Dr. Cody Dunne, a University of Calgary researcher who has tried. The early evidence has come from case reports or small studies that used mannequins and cadavers. 'I think the case is definitely being built,' he said, but more rigorous research is needed. For example, a larger study could compare what happened during choking incidents at nursing homes that stock the devices with those that don't. Dunne noted, however, that evidence for the Heimlich maneuver and back slaps is evolving, too. He co-authored a study last year that found back blows worked better than the Heimlich or chest compressions. 'We're only now getting good evidence on the old choking techniques, let alone these new ones,' he said. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.

OraSure Technologies received takeover bid from industry entrepreneur, sources say
OraSure Technologies received takeover bid from industry entrepreneur, sources say

Yahoo

timean hour ago

  • Yahoo

OraSure Technologies received takeover bid from industry entrepreneur, sources say

By Svea Herbst-Bayliss NEW YORK (Reuters) -Prominent healthcare entrepreneur Ron Zwanziger approached medical device maker OraSure Technologies with a takeover offer, three people familiar with the matter said, in what would mark more consolidation in the heavily fragmented diagnostic industry. In June, Zwanziger submitted an unsolicited all-cash proposal to buy the Bethlehem, Pennsylvania-headquartered company, known for its COVID-19 rapid antigen tests, the sources said. Along with a prominent Wall Street investor and others -- people the sources did not identify -- Zwanziger proposed paying between $3.50 and $4.00 a share for OraSure. OraSure's stock was trading aT $3.18 on Monday morning, leaving it with a market capitalization of $238.6 million. The company's board rejected the offer not long after it was sent, without any discussions between the parties, the three sources said. A company representative did not immediately respond to a request for comment. A representative for Zwanziger, a serial deal maker who cemented his reputation through at-home blood glucose testing, could not be reached for comment. Zwanziger has built and sold a handful of diagnostic companies during his long career, and sold diagnostic test manufacturer Alere Abbott Laboratories in 2017 for around $5.3 billion. The rebuffed offer for OraSure was his second effort to combine with the company, according to one of the sources. In 2022, only a few months after the company named Carrie Eglinton Manner as its chief executive officer, Zwanziger proposed a merger through a stock swap, but terms could not be reached, the source said. OraSure appealed to Zwanziger because of its solid core technology and he thought he could turn around the company's fortunes quickly with a new team, the sources said. The company's stock price has fallen 27% in the last 12 months and is off 77% over the last five years. Quarterly revenue has been dropping since early 2023 as COVID-19 era sales dried up. OraSure has been attempting to diversify its business as a result, buying Sherlock Biosciences late last year for its molecular diagnostics platform. Point of care diagnostic companies offer accurate results in real time to measure cholesterol, and detect flu and pregnancy, for example. But the industry still remains highly fragmented with companies such as Danaher, Siemens, Roche and Thermo Fisher Scientific capturing the biggest market share. Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store